

# ADVANCED MATERIALS

## Supporting Information

for *Adv. Mater.*, DOI: 10.1002/adma.201604932

Localized and Controlled Delivery of Nitric Oxide to the  
Conventional Outflow Pathway via Enzyme Biocatalysis:  
Toward Therapy for Glaucoma

*Rona Chandrawati, Jason Y. H. Chang, Ester Reina-Torres,  
Coline Jumeaux, Joseph M. Sherwood, W. Daniel Stamer,  
Alexander N. Zelikin,\* Darryl R. Overby,\* and Molly M.  
Stevens\**

## Supporting Information

### **Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Towards Therapy for Glaucoma**

*Rona Chandrawati, Jason Y. H. Chang, Ester Reina-Torres, Coline Jumeaux, Joseph M. Sherwood, W. Daniel Stamer, Alexander N. Zelikin,\* Darryl R. Overby,\* and Molly M. Stevens\**

Dr. R. Chandrawati,<sup>[+]</sup><sup>[++]</sup> C. Jumeaux, Prof. M. M. Stevens  
Department of Materials, Department of Bioengineering, and Institute of Biomedical Engineering  
Imperial College London  
London SW7 2AZ, UK  
E-mail: [m.stevens@imperial.ac.uk](mailto:m.stevens@imperial.ac.uk)

Dr. J. Y. H. Chang,<sup>[+]</sup> Dr. E. Reina-Torres, Dr. J. M. Sherwood, Dr. D. R. Overby  
Department of Bioengineering  
Imperial College London  
London SW7 2AZ, UK  
E-mail: [d.overby@imperial.ac.uk](mailto:d.overby@imperial.ac.uk)

Prof. W. D. Stamer  
Department of Ophthalmology  
Duke University School of Medicine  
Durham, NC 27710, USA

Dr. A. N. Zelikin  
Department of Chemistry and iNANO Interdisciplinary Nanoscience Center  
Aarhus University  
Aarhus C 8000, Denmark  
E-mail: [zelikin@chem.au.dk](mailto:zelikin@chem.au.dk)

<sup>[+]</sup> R. C. and J. Y. H. C. contributed equally to this work

<sup>[++]</sup> Present address: School of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, NSW 2006, Australia

**Synthesis of Thiol-Functionalized Poly(methacrylic acid) ( $PMA_{SH}$ ):** PMA with 14 mol% of thiol modification was synthesized through functionalization of the polymer with pyridine dithioethylamine (PDA). A 300 mg of 30 wt% PMA solution ( $M_w$  15000 Da, Polysciences) was charged with 64.6 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 20 mg mL<sup>-1</sup> in 10 mM phosphate buffer pH 7.2, Thermo Scientific) and the mixture was stirred for 15 min. Subsequently, 44.5 mg of PDA (20 mg mL<sup>-1</sup> in 10 mM phosphate buffer pH 7.2, Nanocs) was added to the mixture and the reaction was allowed to proceed overnight. The reaction mixture was purified via extensive dialysis against water and the polymer was isolated via freeze-drying to obtain white powder of  $PMA_{PD}$ . The degree of thiol functionalization of PMA was characterized by measuring the absorbance of released 2-pyridinethione ( $\lambda_{max}$ = 343 nm) using dithiothreitol (DTT, Sigma-Aldrich) and then derived by correlation with a calibration curve of PDA. The reduced form,  $PMA_{SH}$ , was prepared by incubating  $PMA_{PD}$  in a solution of 0.5 M DTT (100 mg mL<sup>-1</sup>) in 20 mM 3-(*N*-morpholino)propanesulfonic acid (MOPS) buffer pH 8.0 for at least 15 min at 37 °C followed by dilution with 20 mM sodium acetate (NaOAc) buffer pH 4.0 to a final concentration of 2 mg mL<sup>-1</sup>.

**Preparation of Alexa Fluor 488-Labeled  $\beta$ -Galactosidase:** A solution of 10 mg mL<sup>-1</sup>  $\beta$ -galactosidase (5 mg) in 100 mM carbonate buffer pH 8.3 was incubated with 100  $\mu$ L of Alexa Fluor 488 succinimidyl ester (1 mg mL<sup>-1</sup> in DMSO, Molecular Probes). The reaction was allowed to proceed overnight and excess Alexa Fluor 488 was removed through purification by centrifugal filter devices.

**Assembly of  $\beta$ -Galactosidase-Loaded Capsules:** Amine-functionalized 1  $\mu$ m-diameter SiO<sub>2</sub> particles (5 wt% solution, microParticles GmbH) were washed with three centrifugation/redispersion cycles (1200 g, 30 s) with 10 mM Tris-EDTA buffer pH 7.5.

$\beta$ -Galactosidase (1 mg mL<sup>-1</sup> in 10 mM Tris-EDTA buffer pH 7.5, Sigma-Aldrich) was added to the particle solution and adsorption was allowed to proceed for 1 h with constant shaking. The resulting enzyme-coated particles were washed twice with 10 mM Tris-EDTA buffer pH 7.5 and twice with 20 mM NaOAc buffer pH 4.0. Assembly of polymer multilayers was achieved by alternately incubating the particles with thiol-functionalized poly(methacrylic acid) (PMA<sub>SH</sub>, 1 mg mL<sup>-1</sup>, 15 min) and poly(*N*-vinylpyrrolidone) (PVP, Mw 10000 Da, 1 mg mL<sup>-1</sup>, 15 min, Sigma-Aldrich) in NaOAc buffer with constant shaking. The particles were washed with three centrifugation/redispersion cycles (1200 g, 30 s) with NaOAc buffer between layers and the process was repeated until four bilayers of PMA<sub>SH</sub>/PVP were assembled. The thiols within the polymer layers were crosslinked with 2,2'-dithiodipyridine (0.5 mg mL<sup>-1</sup>, 15 h, Sigma-Aldrich) in NaOAc buffer. Hollow capsules containing  $\beta$ -galactosidase were obtained by dissolving the SiO<sub>2</sub> cores using a 2 M hydrofluoric acid (HF)/8 M ammonium fluoride (NH<sub>4</sub>F) solution for 2 min, followed by multiple centrifugation/washing cycles (4500 g, 3 min). *Caution! HF and NH<sub>4</sub>F are highly toxic. Extreme care should be taken when handling HF and NH<sub>4</sub>F solutions and only small quantities should be prepared.*


***Formation of  $\beta$ -Gal-NONOate-Loaded Liposomes:*** 1-Palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC, 5 mg, Avanti Polar Lipids) was dissolved in chloroform and dried by evaporation of the chloroform under nitrogen for 1 h. The dry lipid film was hydrated with 1 mL of  $\beta$ -gal-NONOate (25 – 75  $\mu$ M in DBG solution, Cayman Chemical).  $\beta$ -Gal-NONOate-loaded liposomes were obtained by repeated extrusion (31 times) of the lipid solution through 1  $\mu$ m polycarbonate membranes (Whatman) using a mini-extruder (Avanti Polar Lipids). Non-encapsulated  $\beta$ -gal-NONOate was removed from the liposome suspension by centrifugal

filter devices. Encapsulation efficiency of NONOate-loaded liposomes was reported to be ca. 35%.<sup>[1]</sup>


**Release of Nitric Oxide by  $\beta$ -Galactosidase/ $\beta$ -Gal-NONOate Reactions:** NO release kinetics from non-encapsulated and encapsulated  $\beta$ -galactosidase/ $\beta$ -gal-NONOate was compared and determined with a NO-sensitive electrode (ISO-NO Mark II, World Precision Instruments). The NO electrode was first calibrated following the manufacturer's instruction manual. Briefly, the NO probe was placed in a 0.1 M H<sub>2</sub>SO<sub>4</sub>/0.1 M KI solution to polarize the sensor and to obtain a current baseline. NO calibration curve was obtained by measuring changes in current in response to incremental volumes of 50  $\mu$ M NaNO<sub>2</sub> added to the H<sub>2</sub>SO<sub>4</sub>/KI solution within a glass vial. Conversion of NaNO<sub>2</sub> to NO occurred rapidly and followed a 1:1 stoichiometry, such that NO concentration was dictated by the added concentration of NaNO<sub>2</sub>. To determine NO release kinetics via  $\beta$ -galactosidase catalytic reactions, the NO probe was first equilibrated in a 0.1 mg mL<sup>-1</sup>  $\beta$ -galactosidase in DBG solution for 2 h at 37 °C. Incremental volumes of 50  $\mu$ M  $\beta$ -gal-NONOate in DBG solution were added into the  $\beta$ -galactosidase solution and changes in current were measured over time. To determine NO release kinetics from  $\beta$ -galactosidase encapsulated in PMA capsules and  $\beta$ -gal-NONOate loaded in liposomes, the NO probe was equilibrated in a suspension of  $\beta$ -galactosidase-loaded capsules in DBG solution (10<sup>6</sup> capsules  $\mu$ L<sup>-1</sup>) for 2 h at 37 °C. Liposomes containing different concentrations of  $\beta$ -gal-NONOate (25 – 75  $\mu$ M, 10<sup>6</sup> liposomes  $\mu$ L<sup>-1</sup>) were added into the capsule solution and changes in current were measured over time. All NO measurements were performed in mock aqueous humor solution (DBG solution, typically used for *ex vivo* perfusions) at 37 °C on a hot plate with continuous mixing. The number of  $\beta$ -galactosidase-loaded capsules and  $\beta$ -gal-NONOate-loaded liposomes was determined by flow cytometry (BD LSRFortessa) and nanoparticle tracking analysis (NTA NanoSight LM10), respectively.

**Animal Husbandry:** All experiments were conducted in compliance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research under UK Home Office Project License approval for research at Imperial College London. This study used C57BL/6 male wild-type (WT) mice subjected to *in vivo* intracameral injections followed by *ex vivo* eye perfusions. Mice were 10 – 12 wk of age, housed in individually ventilated cages, fed *ad libitum*, and maintained at 21 °C with a 12:12-h light-dark cycle, with lights on from 7 AM to 7 PM.

[1] D. J. Suchyta, M. H. Schoenfish, *Mol. Pharm.* **2015**, *12*, 3569.



**Figure S1.** Nitric oxide (NO) calibration curve obtained by measuring changes in current in response to incremental volumes of 50  $\mu\text{M}$   $\text{NaNO}_2$  added to a 0.1 M  $\text{H}_2\text{SO}_4$ /0.1 M KI solution.



**Figure S2.** Fluorescence microscopy image of poly(methacrylic acid) capsules containing Alexa Fluor 488-labeled  $\beta$ -galactosidase.